Supercharged immune cells take on childhood cancers
NCT ID NCT02789228
First seen Apr 05, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This early-phase trial tests a new type of cell therapy for children and young adults with solid tumors that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are trained in the lab to recognize and attack multiple cancer-related targets. The main goal is to see if this approach is safe, while also checking for any signs that the tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Children's National Medical Center
Washington D.C., District of Columbia, 20010, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tumor associated antigen lymphocytes (TAA-CTL), a type of immune cell therapy
What this could lead to
If this works, it could point toward a new treatment option for children and young adults with hard-to-treat solid tumors that have not responded to standard therapy.
What could go wrong
This is a very early (Phase 1) and small study (28 participants) focused mainly on safety. The therapy may not shrink tumors or improve survival, and there is a risk of serious side effects like infusion reactions or graft-versus-host disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.